BioCentury
ARTICLE | Clinical News

IDEC-131: Completed Phase II study enrollment

October 25, 1999 7:00 AM UTC

Idec Pharmaceuticals Corp. (IDPH), San Diego, Calif. Product: IDEC-131 Business: Autoimmune/Inflammation Therapeutic category: Antibody Target: CD40 ligand (also called gp39 or CD154) on activated T...